Edition:
India

DexCom Inc (DXCM.OQ)

DXCM.OQ on NASDAQ Stock Exchange Global Select Market

118.12USD
1:30am IST
Change (% chg)

$-0.70 (-0.59%)
Prev Close
$118.82
Open
$119.26
Day's High
$120.01
Day's Low
$117.25
Volume
300,375
Avg. Vol
444,655
52-wk High
$156.16
52-wk Low
$72.62

Latest Key Developments (Source: Significant Developments)

Dexcom Inc - Board Committed Dexcom To Restructuring Plan That Will Result In Transition Of Some Operations To Philippines
Friday, 22 Feb 2019 

Feb 21 (Reuters) - DexCom Inc ::DEXCOM INC - ON FEB 20, BOARD COMMITTED DEXCOM TO RESTRUCTURING PLAN THAT WILL RESULT IN TRANSITION OF CERTAIN OF CO'S OPERATIONS TO PHILIPPINES.DEXCOM INC - EXPECTS RESTRUCTURING TO IMPACT ABOUT 350 FULL TIME EMPLOYEES, OR ABOUT 13% OF CO'S TOTAL FULL TIME WORKFORCE AS OF DEC 31, 2018.DEXCOM INC - MOST OF AFFECTED EMPLOYEES UNDER RESTRUCTURING CURRENTLY WORK IN CO'S FACILITIES IN SAN DIEGO, CALIFORNIA AND MESA, ARIZONA.DEXCOM INC - RESTRUCTURING COSTS ARE PRIMARILY EXPECTED TO BE INCURRED THROUGHOUT 2019 AND CO EXPECTS TO RECORD MAJORITY OF CHARGES IN H1 OF 2019.DEXCOM INC - EXPECTS MAJORITY OF RESTRUCTURING ACTIVITIES TO BE COMPLETED BY END OF 2019 - SEC FILING.  Full Article

Dexcom Inc - Entered Into An Amended And Restated Credit Agreement With JPMorgan Chase Bank, N.A. - SEC Filing
Saturday, 22 Dec 2018 

Dec 21 (Reuters) - DexCom Inc ::DEXCOM INC - ENTERED INTO AN AMENDED AND RESTATED CREDIT AGREEMENT WITH JPMORGAN CHASE BANK, N.A. - SEC FILING.DEXCOM INC - AMENDED CREDIT AGREEMENT DATED JUNE 16, 2016 PROVIDES FOR A $200 MILLION REVOLVING CREDIT AGREEMENT.DEXCOM INC - HAS OPTION TO INCREASE AMOUNT UNDER AMENDED CREDIT AGREEMENT BY UP TO AN ADDITIONAL $300 MILLION.DEXCOM INC - AMENDED CREDIT AGREEMENT MATURES ON DECEMBER 19, 2023.  Full Article

DexCom Q3 Non-GAAP Earnings Per Share $0.17
Wednesday, 7 Nov 2018 

Nov 6 (Reuters) - DexCom Inc ::DEXCOM REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 NON-GAAP EARNINGS PER SHARE $0.17.Q3 GAAP EARNINGS PER SHARE $0.52.Q3 REVENUE $266.7 MILLION VERSUS I/B/E/S VIEW $241.3 MILLION.Q3 EARNINGS PER SHARE VIEW $-0.10 -- THOMSON REUTERS I/B/E/S.SEES 2018 REVENUE OF APPROXIMATELY $975 MILLION, VERSUS PRIOR FORECAST OF $925 MILLION.SEES 2018 GROSS PROFIT MARGIN OF APPROXIMATELY 64%, CONSISTENT WITH COMPANY'S MOST RECENT OUTLOOK.  Full Article

Dexcom Acquires TypeZero Technologies
Thursday, 23 Aug 2018 

Aug 22 (Reuters) - DexCom Inc ::DEXCOM ACQUIRES TYPEZERO TECHNOLOGIES.DEXCOM INC - TERMS OF TRANSACTION WERE NOT DISCLOSED..DEXCOM INC - EXPECTS TO SUPPORT FIRST COMMERCIAL LAUNCH OF AN AID SYSTEM USING INCONTROL ALGORITHM IN 2019.  Full Article

FDA Authorizes Marketing Of New Dexcom G6 CGM Eliminating Need For Fingerstick Blood Testing
Wednesday, 28 Mar 2018 

March 27 (Reuters) - Dexcom Inc ::FDA AUTHORIZES MARKETING OF THE NEW DEXCOM G6® CGM ELIMINATING NEED FOR FINGERSTICK BLOOD TESTING FOR PEOPLE WITH DIABETES.DEXCOM INC - EXPECTS TO LAUNCH DEXCOM G6 CGM SYSTEMLATER THIS YEAR.  Full Article

U.S. FDA Says Permitted Marketing Of Dexcom G6 Integrated Continuous Glucose Monitoring System
Wednesday, 28 Mar 2018 

March 27 (Reuters) - Dexcom Inc ::U.S. FDA SAYS PERMITTED MARKETING OF THE DEXCOM G6 INTEGRATED CONTINUOUS GLUCOSE MONITORING (ICGM) SYSTEM.U.S. FDA SAYS AUTHORIZATION OF ICGM SYSTEM CLASSIFIES THIS NEW TYPE OF DEVICE IN CLASS II & SUBJECTS IT TO CERTAIN CRITERIA CALLED SPECIAL CONTROLS.  Full Article

Waveform Technologies Receives Favorable Decision On Critical Glucose Monitoring Patents
Friday, 9 Mar 2018 

March 8 (Reuters) - Waveform Technologies::SAYS ‍PTAB RULED 2 EARLY PATENTS HELD BY WAVEFORM ARE NOT INVALID, BASED ON CHALLENGES BROUGHT BY DEXCOM​.SAYS RECEIVES FAVORABLE DECISION ON CRITICAL GLUCOSE MONITORING PATENTS.  Full Article

Dexcom Inc Q4 GAAP Loss Per Share $0.11
Wednesday, 28 Feb 2018 

Feb 27 (Reuters) - Dexcom Inc ::DEXCOM REPORTS RECORD FOURTH QUARTER AND FISCAL YEAR 2017 FINANCIAL RESULTS.Q4 GAAP LOSS PER SHARE $0.11.Q4 NON-GAAP EARNINGS PER SHARE $0.10 EXCLUDING ITEMS.Q4 REVENUE ROSE 29 PERCENT TO $221 MILLION.SEES FY 2018 REVENUE $830 MILLION TO $850 MILLION.  Full Article

DexCom Says Preliminary Q4 Revenue Was $218 Mln
Tuesday, 9 Jan 2018 

Jan 8 (Reuters) - DexCom Inc ::DEXCOM REPORTS RECORD PRELIMINARY, UNAUDITED REVENUE FOR THE FOURTH QUARTER AND FISCAL YEAR 2017 AND PROVIDES INITIAL 2018 OUTLOOK.SEES FY 2018 REVENUE ABOUT $830 MILLION TO $850 MILLION.SEES FY 2017 REVENUE ABOUT $715 MILLION.PRELIMINARY Q4 REVENUE $218 MILLION VERSUS I/B/E/S VIEW $212.6 MILLION .FY2017 REVENUE VIEW $710.2 MILLION -- THOMSON REUTERS I/B/E/S.FY2018 REVENUE VIEW $854.6 MILLION -- THOMSON REUTERS I/B/E/S.Q4 REVENUE VIEW $212.7 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Dexcom announces development agreement with Lilly
Tuesday, 21 Nov 2017 

Nov 21 (Reuters) - Dexcom Inc ::Dexcom announces development agreement with Lilly to integrate Dexcom CGM into connected diabetes ecosystem.Says ‍companies expect to combine Lilly's smart insulin delivery devices and Dexcom CGM.  Full Article